2021

Rebus Biosystems Continues Rapid Expansion of Scientific Team

August 25, 2021

SANTA CLARA, CA – Rebus Biosystems, Inc., (“Rebus Bio”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced Tarif Awad, a highly experienced technical and commercial leader within the world of life sciences, has joined Rebus Bio as VP Scientific Affairs.

Read more

Rebus Biosystems Prepares for Rapid Growth with Senior Leadership Appointments

March 25, 2021

SANTA CLARA, Calif. – Rebus Biosystems, Inc., a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the appointment of Neil Kennedy as Chief Commercial Officer (CCO) and Scott Kothlow as Chief Financial Officer (CFO).

Read more

Rebus Biosystems Launches Automated Spatial Omics Platform

March 1, 2021

SANTA CLARA, Calif. – Rebus Biosystems, Inc., a life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the launch of the Rebus EsperTM spatial omics platform. The new spatial omics platform will allow researchers to better understand the biology of tissues and lead to advancements in neuroscience, cancer, infectious disease and immunology.

Read more
2020

Rebus Biosystems, Inc. Announces $20 Million Series B Financing to Support Commercialization of Automated Spatial Omics Solution

November 19, 2020

SANTA CLARA, Calif. — Rebus Biosystems, Inc., a life science technology company building innovative tools to enable spatial omics without compromise, today announced the closing of a $20 million Series B financing round, led by Illumina Ventures and joined by Lifecore PartnersNcore VenturesXolon InvestCTK Investments, Ray Co., Ltd., Seegene Medical Foundation, LabGenomics Co., Ltd., and Timefolio Asset Management. 

Read more